心力衰竭患者通过心脏康复改善肌少症状态的临床影响
本研究为单中心回顾性队列,纳入546例心力衰竭住院患者,在出院时及至少3个月门诊心脏康复后评估肌少症状态,分为无肌少症、改善和未改善三组。多因素Cox回归显示,未改善组全因死亡风险显著高于无肌少症组(HR 2.603,95%CI 1.375-4.930,P=.004),而改善组与无肌少症组无显著差异。
要点
- 心衰患者门诊心脏康复后肌少症未改善与全因死亡风险升高相关。
- 肌少症改善组死亡风险与无肌少症组无显著差异。
- 肌少症可能是改善心衰患者预后的重要干预靶点。
核心结论
- 心衰患者接受门诊心脏康复后肌少症状态未改善与全因死亡风险升高相关。
- 肌少症可能是改善心衰患者预后的重要靶点。
研究设计与样本
- 纳入出院时及至少3个月门诊心脏康复后评估肌少症状态的心衰患者,共546例,中位年龄70岁,男性63.6%。
主要发现
- 546例中无肌少症组377例(69.0%),改善组54例(9.9%),未改善组115例(21.1%)。
- 多因素Cox回归显示未改善组全因死亡风险显著高于无肌少症组(HR 2.603,95%CI 1.375-4.930,P=.004)。
- 改善组与无肌少症组全因死亡风险无显著差异(HR 1.403,95%CI 0.598-3.293,P=.43)。
临床怎么用
- 对心衰住院患者应在出院时及门诊心脏康复后评估肌少症状态。
- 关注心脏康复后肌少症未改善的患者,因其全因死亡风险较高。
局限性
- 本研究为单中心回顾性队列研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Sarcopenia in patients with heart failure (HF) is associated with poor prognosis. Cardiac rehabilitation (CR) decreases the incidence of adverse events in patients with HF. However, the clinical implications of improving sarcopenia status through CR remain unclear. This study investigated the relationship between the changes in sarcopenia status in patients with HF undergoing outpatient CR and the risk of mortality and adverse events. DESIGN: This was a retrospective cohort study of patients hospitalized at the Kitasato University Hospital Cardiovascular Center for the treatment of HF between January 2007 and December 2020. SETTING AND PARTICIPANTS: Patients with HF whose sarcopenia status was assessed at hospital discharge and following at least 3 months of outpatient CR were included. Based on the sarcopenia status, all patients were divided into 3 groups: patients without sarcopenia at discharge (ie, robust), patients with sarcopenia at discharge but no sarcopenia following CR (ie, improved), and patients with sarcopenia at discharge and following CR (ie, unimproved). METHODS: Cox regression analysis was used to examine the risk of all-cause death associated with the 3 sarcopenia status groups. RESULTS: Of 546 patients with HF (median age: 70 years; male: 63.6%), 377 (69.0%), 54 (9.9%), and 115 (21.1%) were classified as robust, improved, and unimproved, respectively. Multivariate Cox regression analysis showed that the unimproved group had a significantly greater risk of all-cause death when compared to the robust group [hazard ratio (HR) 2.603, 95% CI 1.375-4.930, P = .004], but it did not differ from the improved group (HR 1.403, 95% CI 0.598-3.293, P = .43). CONCLUSIONS AND IMPLICATIONS: No improvement in sarcopenia status in patients with HF undergoing outpatient CR was associated with a higher risk of all-cause death. Sarcopenia may be an important target to improve the prognosis of patients with HF.
引用
- Shakuta S, Noda T, Kamiya K, et al. Clinical Impact of Improvement in Sarcopenia through Cardiac Rehabilitation in Patients with Heart Failure. J Am Med Dir Assoc. 2024. PMID: 38182121. doi:10.1016/j.jamda.2023.10.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。